richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
we have sent you a verification email. to verify, just follow the link in the message
.
., although most have plans that will adequately improve air quality.
.
.
.